Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
172 hedge funds and large institutions have $2.15B invested in Turning Point Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 75 increasing their positions, 55 reducing their positions, and 41 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
36% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 55
9% less funds holding
Funds holding: 190 → 172 (-18)
28% less capital invested
Capital invested by funds: $2.98B → $2.15B (-$838M)
39% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 41
78% less call options, than puts
Call options by funds: $349K | Put options by funds: $1.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$33.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$31.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$26.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.5M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$22.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$41.6M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$38.4M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$34.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$34M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$21.5M |
TPTX Hedge Fund Activity: Q4 2021 in Review
172 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q4 2021, worth a combined $2.15B — down 28% from $2.98B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of TPTX and 25 opened new positions — a net loss of 16 holders — while 55 trimmed existing stakes and 75 added.
The largest buyer was AllianceBernstein, adding an estimated $33.8M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $41.6M sold.
- 172 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q4 2021, down from 190 in Q3 2021.
- Funds reported $2.15B of Turning Point Therapeutics, Inc. Common Stock stock for Q4 2021, down 28% quarter-over-quarter.
- 25 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q4 2021 and 41 closed out, a net change of -16 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q4 2021 was AllianceBernstein, an estimated $33.8M added.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q4 2021 was Alkeon Capital Management, an estimated $41.6M sold.
Based on aggregated 13F filings for Q4 2021.